PRPF31 Gene

PRPF31 Gene

Overview

The PRPF31 (Pre-mRNA Processing Factor 31) gene encodes a core component of the U4/U6.U5 tri-snRNP complex, which is essential for pre-mRNA splicing. PRPF31 is a spliceosomal protein that plays a critical role in the spliceosome assembly and catalytic steps during precursor messenger RNA processing. Mutations in PRPF31 are classically associated with retinitis pigmentosa, but emerging evidence suggests broader implications for neurodegenerative diseases through its essential role in neuronal RNA processing and splicing regulation.

Introduction

PRPF31 is a member of the PRP (Pre-mRNA processing) protein family and functions as an essential spliceosome component. The protein is conserved across eukaryotes and is ubiquitously expressed, with particularly high expression in neuronal tissues. The spliceosome is the large ribonucleoprotein complex responsible for removing introns from pre-mRNA, and PRPF31 is one of the key proteins that stabilize the catalytic core of this machinery.

While PRPF31 mutations are most strongly associated with retinitis pigmentosa—a hereditary retinal degeneration leading to progressive vision loss—recent research has highlighted its potential role in neurodegeneration more broadly. Neurons are particularly dependent on precise RNA splicing due to their complex and specialized gene expression patterns, and any disruption in splicing machinery can have profound effects on neuronal survival and function.
<div class="infobox infobox-gene">

PRPF31 Gene

Overview

The PRPF31 (Pre-mRNA Processing Factor 31) gene encodes a core component of the U4/U6.U5 tri-snRNP complex, which is essential for pre-mRNA splicing. PRPF31 is a spliceosomal protein that plays a critical role in the spliceosome assembly and catalytic steps during precursor messenger RNA processing. Mutations in PRPF31 are classically associated with retinitis pigmentosa, but emerging evidence suggests broader implications for neurodegenerative diseases through its essential role in neuronal RNA processing and splicing regulation.

Introduction

PRPF31 is a member of the PRP (Pre-mRNA processing) protein family and functions as an essential spliceosome component. The protein is conserved across eukaryotes and is ubiquitously expressed, with particularly high expression in neuronal tissues. The spliceosome is the large ribonucleoprotein complex responsible for removing introns from pre-mRNA, and PRPF31 is one of the key proteins that stabilize the catalytic core of this machinery.

While PRPF31 mutations are most strongly associated with retinitis pigmentosa—a hereditary retinal degeneration leading to progressive vision loss—recent research has highlighted its potential role in neurodegeneration more broadly. Neurons are particularly dependent on precise RNA splicing due to their complex and specialized gene expression patterns, and any disruption in splicing machinery can have profound effects on neuronal survival and function.
<div class="infobox infobox-gene">

| | |
|---|---|
| Gene Symbol | PRPF31 |
| Gene Name | Pre-mRNA Processing Factor 31 |
| Chromosome | 19q13.42 |
| NCBI Gene ID | [26121](https://www.ncbi.nlm.nih.gov/gene/26121) |
| OMIM | [607395](https://www.omim.org/entry/607395) |
| Ensembl ID | [ENSG00000105618](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105618) |
| UniProt | [O94973](https://www.uniprot.org/uniprotkb/O94973/entry) |
| Associated Diseases | Retinitis Pigmentosa, Retinal Degeneration, Potential Neurodegeneration |

</div>

Function

Spliceosome Component

PRPF31 is a core component of the U4/U6.U5 tri-snRNP (small nuclear ribonucleoprotein particle), which forms the major building block of the spliceosome. The tri-snRNP contains:

• U4 snRNA — serves as an intronic sequence placeholder
• U6 snRNA — the catalytic component of the spliceosome
• U5 snRNA — recognizes the 5' and 3' splice sites
• PRPF31 — stabilizes the U4/U6 interaction and facilitates spliceosome assembly
• Other proteins — including PRPF3, PRPF4, and ABC1

Spliceosome Assembly Cycle

The spliceosome undergoes a series of coordinated assembly steps:

PRPF31 is particularly important for the B to B* transition, where the spliceosome becomes catalytically active.

Role in Neuronal Gene Expression

Neurons have particularly complex splicing patterns, with extensive alternative splicing generating diverse protein isoforms essential for synaptic function, neuronal development, and circuit formation. PRPF31-mediated splicing affects:

• Synaptic proteins — NMDA receptor subunits, AMPA receptor variants, scaffolding proteins
• Ion channels — voltage-gated calcium and potassium channel isoforms
• Axon guidance molecules — netrins, semaphorins, ephrins
• Transcription factors — neuronal specific splicing regulators

Disease Associations

Retinitis Pigmentosa

PRPF31 mutations are among the most common causes of autosomal dominant retinitis pigmentosa (ADRP). The disease mechanism involves:

• haploinsufficiency — 50% reduction in functional PRPF31 leads to photoreceptor degeneration
• Splicing defects — mutant PRPF31 produces abnormal spliceosome function
• Photoreceptor vulnerability — rods are particularly sensitive to splicing disruption

Neurodegeneration Implications

While not classically considered a neurodegeneration gene, PRPF31's essential function in RNA splicing suggests potential roles in:

• Amyotrophic Lateral Sclerosis (ALS) — splicing defects have been documented in ALS patient tissue
• Frontotemporal Dementia (FTD) — RNA processing dysfunction is a common feature
• Spinal Muscular Atrophy — splicing machinery defects contribute to disease
• Alzheimer's Disease — aberrant splicing has been reported in AD brain tissue

PRPF31 in Alzheimer's Disease

Emerging evidence links PRPF31 to Alzheimer's disease pathogenesis[@singh2023]:

Splicing Dysregulation in AD:

• Genome-wide splicing analysis reveals widespread abnormalities in AD brain
• PRPF31 expression is reduced in AD temporal cortex
• Affected transcripts include those involved in synaptic function
• Tau pathology correlates with splicing defects

• APP alternative splicing generates toxic isoforms
• Tau exon 10 mis-splicing affects isoform ratios
• Synaptic protein isoforms altered in disease
• Mitochondrial transcripts affected

PRPF31 in Parkinson's Disease

PRPF31 may contribute to Parkinson's disease through RNA processing mechanisms[@liu2024]:

Altered Splicing Patterns:

• PD brain tissue shows distinct splicing signatures
• Mitochondrial function transcripts affected
• Autophagy-related genes mis-spliced
• Synaptic transmission transcripts altered

• SNCA splicing may be PRPF31-dependent
• Aggregation-prone isoforms potentially regulated
• RNA binding protein interactions
• Stress granule formation link

PRPF31 in ALS and FTD

The spliceosome is directly implicated in ALS and FTD pathogenesis[@choi2023]:

RNA Processing Defects:

• C9orf72 hexanucleotide expansion affects splicing
• PRPF31 variants modify disease risk
• TDP-43 pathology impacts spliceosome function
• Loss of nuclear RNA processing

• ASO therapy targeting specific splicing events
• Spliceosome-modulating drugs
• Gene replacement strategies

Expression

Tissue Distribution

PRPF31 is expressed in virtually all tissues, with highest levels in:

• Retina and photoreceptor cells
• Brain (cerebral cortex, hippocampus)
• Testis
• Heart and skeletal muscle

Subcellular Localization

• Nuclear — PRPF31 localizes to nuclear speckles, where spliceosome assembly occurs
• Nucleolus — some accumulation in nucleolar regions
• Cytoplasmic — limited cytoplasmic localization in neurons

Regulation

PRPF31 expression is regulated by:

• Transcription factors — SP1, AP-2 influence basal expression
• Cell cycle — expression peaks in S phase
• Stress responses — heat shock and oxidative stress affect levels
• Developmental stage — higher expression during neural development

Related Pathways

Spliceosome Pathway

PRPF31 is part of the major spliceosome pathway, interacting with:

• U1 snRNP (5' splice site recognition)
• U2 snRNP (branch point binding)
• U4/U6.U5 tri-snRNP (catalytic core)
• NTC (Nineteen Complex) — required for spliceosome activation

RNA Processing

PRPF31 participates in:

• Pre-mRNA splicing
• Alternative splicing regulation
• mRNA export (coupled to splicing)
• NMD (nonsense-mediated decay) coupling

Molecular Mechanisms

Spliceosome Assembly and Catalysis

PRPF31 plays essential roles in the spliceosome catalytic cycle[@zhang2023]:

Tri-snRNP Integration:

• PRPF31 stabilizes the U4/U6.U5 tri-snRNP
• Facilitates proper snRNA base-pairing
• Required for spliceosome activation
• ATP-dependent conformational changes

• B to B* complex transition requires PRPF31
• Release of U4 snRNA enables catalysis
• Quality control checkpoint function
• Disassembly and recycling

Neuronal Splicing Specificity

Neurons have particularly complex splicing requirements[@chen2022]:

Synaptic Protein Isoforms:

• NMDA and AMPA receptor subunit variants
• Synaptic scaffolding proteins
• Ion channel diversity
• Activity-dependent splice variants

• Neuron-specific splicing factors
• Alternative exon usage
• Splicing factor expression changes in aging
• Disease-related splicing alterations

PRPF31 and Protein Homeostasis

Alternative Splicing in Neurodegeneration

Aberrant splicing contributes to protein homeostasis collapse in neurodegeneration:

Protein Aggregate Formation:

• Mis-spliced proteins more prone to misfolding
• Clearance pathway dysfunction
• Sequestration of quality control machinery
• Propagation of proteostatic stress

• ATG transcripts alternatively spliced
• Lysosomal function affected
• Aggregate clearance impaired
• Cellular stress response

Ribonucleoprotein Assembly

PRPF31 functions within the context of larger RNA-protein complexes:

Stress Granules:

• Splicing factors accumulate in stress granules
• PRPF31 localization during cellular stress
• Connection to FTD pathology
• Therapeutic targeting potential

• Storage and assembly sites for spliceosome components
• Dynamic trafficking between compartments
• Age-related changes
• Disease-related disruption

PRPF31 in Aging

Age-Related Splicing Changes

Aging affects spliceosome function and PRPF31 activity[@kour2024]:

Spliceosome Aging:

• Declined splicing fidelity with age
• Accumulation of splicing errors
• Increased aberrant splicing events
• Cellular consequences

• Post-mitotic neurons cannot dilute errors
• Cumulative splicing defects
• Synaptic dysfunction
• Age-related disease onset

Therapeutic Implications

Aging-related splicing changes offer therapeutic opportunities:

Splicing Enhancement:

• Compounds that boost spliceosome function
• Targeting age-related splicing decline
• Preventive interventions
• Disease modification

• ASO-mediated splice correction
• Gene therapy approaches
• Protein-based interventions

Biomarkers and Diagnostics

Splicing Biomarkers

Splicing patterns may serve as disease biomarkers:

Blood-Based Markers:

• Splice variant detection in PBMCs
• Correlation with disease state
• Non-invasive monitoring
• Clinical utility studies

• Neuron-derived splicing products
• Disease-specific patterns
• Prognostic value
• Therapeutic monitoring

Genetic Testing

PRPF31 testing considerations:

Retinitis Pigmentosa:

• Diagnostic testing available
• Family counseling
• Genotype-phenotype correlations
• Treatment planning

• Research use only currently
• Variant interpretation challenges
• Multiple genetic contributors
• Polygenic risk considerations

Experimental Models

Mouse Models

Prpf31 Mutant Mice[@freund2024]:

• Haploinsufficient mice model PRPF31 RP
• Photoreceptor degeneration
• Retinal function decline
• Splicing defects in neural tissues

• Neuron-specific deletion models
• Disease mechanism studies
• Therapeutic testing platforms

Cellular Models

Patient-Derived Cells[@patel2024]:

• iPSC-derived retinal organoids
• Neuronal differentiation protocols
• Disease modeling
• Gene correction studies

• Minigene reporter systems
• RNA-seq analysis
• spliceosome activity measurements

Therapeutic Implications

Spliceosome-Targeted Therapies

The spliceosome represents a promising therapeutic target[@boudreau2022]:

ASO Therapy:

• Antisense oligonucleotides correct aberrant splicing
• Splice-switching oligonucleotides
• Tissue delivery optimization
• Clinical trials in progress

• Spliceosome-enhancing compounds
• Selective splicing modulators
• Combination approaches
• Safety considerations

Gene Therapy

Viral Vector Delivery[@patel2024]:

• AAV-mediated PRPF31 expression
• Optimized promoters for retinal expression
• Dose-finding studies
• Clinical translation

• Allele-specific editing
• Splice-site correction
• Regulatory element targeting

Clinical Trial Landscape

Current clinical approaches targeting RNA splicing:

Retinitis Pigmentosa:

• Gene replacement trials ongoing
• AAV-PRPF31 safety studies
• Visual acuity endpoints
• Long-term follow-up

• ASO trials for other splicing factors
• Biomarker development
• Patient selection criteria
• Combination approaches

Regulatory Considerations

FDA Pathways:

• Orphan drug designation
• Accelerated approval
• Biomarker-based endpoints
• Pediatric considerations

• EMA COMP designation
• Japanese conditional approval
• International collaboration

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [RNA Splicing](/mechanisms/rna-splicing)
• [Spliceosome](/mechanisms/spliceosome)

Therapeutic Implications

Spliceosome-Targeted Therapies

Given PRPF31's essential role in RNA splicing, therapeutic strategies are being developed:

Clinical Outlook

Current research directions include:

• [Developing ASOs that selectively modulate PRPF31 splicing](/genes/prpf31)
• [Understanding tissue-specific vulnerability (retina vs. neurons)](/cell-types/neurons)
• [Biomarker development for therapeutic monitoring](/genes/ar)

Mermaid Diagram: PRPF31 Functions and Disease

References